Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Toxicologic Pathology
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by MacDonald, J. S.
Right arrow Articles by Halleck, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MacDonald, J. S.
Right arrow Articles by Halleck, M. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

The Toxicology of HMG—CoA Reductase Inhibitors: Prediction of Human Risk

James S. MacDonald

Schering-Plough Research Institute, Kenilworth, New Jersey 07033, USA, james.macdonald{at}spcorp.com

Margaretann M. Halleck

Bristol-Myers Squibb Research Institute, New Brunswick, New Jersey 08903-0191, USA

The discovery that 3-hydroxy-3-methyglutaryl coenzyme A reductase was a rate-determining step in the biosynthesis of cholesterol led to the discovery of inhibitors of this enzyme. To support the development of these agents (statins) as potential hypocholesterolemic drugs, a variety of preclinical studies were conducted in several animal species. Not unexpectedly due to the central role played by mevalonic acid and its products including cholesterol in development and maintenance of cellular homeostasis, administration of high dosage levels of these agents led to the expression of a broad variety of adverse effects in many different tissues. Using the tools of toxicologic pathology and classical risk assessment, these varied toxicities were evaluated by many groups relative to the conditions of use in human therapy and a perspective was developed on potential human risk. These approaches of mechanism-based risk assessment predicted that most of the adverse effects observed in animals would not be seen under conditions of human use and supported the successful introduction of one of the most important classes of human medicines.

Key Words: Statin toxicology • mechanism-based risk assessment • HMG-CoA reductase inhibitors • prediction of human toxicity.

References

  • Alberts, A.W., Chen, J., Kuron, G., Hunt, V., Huff, J., Hoffman, C., Rothrock, J., Lopez, M., Joshua, H., Harris, E., Patchett, A., Monaghan, R., Currie, S., Stapley, E., Albers-Schoenberg, G., Hensens, O., Hirshfield, J., Hoogsteen, K., Liesch, J., and Springer, J. (1980). Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme a reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 77(7), 3957— 61.[Abstract/Free Full Text]
  • Alberts, A.W., MacDonald, J.S., Till, A.E., and Tobert, J.A. (1989). Lovastatin. Cardiovascular Drug Reviews 7(2), 89—109.[CrossRef][Web of Science]
  • Alcala, J., Cenedella, R.J., and Katar, M. (1985). Limited proteolysis of MP26 in lens fiber plasma membranes of the U18666A-induced cataract in rats. Cur Eye Res 4, 1001—1005.
  • Anitschkow, N., and Chalatow, S. (1913). Classics in arteriosclerosis research: on experimental cholesterin steatosis and its significance in the origin of some pathological processes. Translated by Mary Z. Pelias, 1913. Arteriosclerosis 3(2), 178—82.
  • Backes, J.M., and Howard, P.A. (2003). Association of HMG-CoA reductase inhibitors with neuropathy. The Annals of Pharmacotherapy 37, 274— 78.[Abstract/Free Full Text]
  • Ballantyne, C.M., Corsini, A., Davidson, M.H., Holdaas, H., Jacobson, T.A., Leitersdorf, E., Marz, W., Reckless, J.P.D., and Stein, E.A. (2003). Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 163, 553—64.[Abstract/Free Full Text]
  • Bays, H., and Dijorne, C. (1998). Drug interactions of lipid-alterating drugs. Drug Saf 5, 355—71.
  • Berry, P.H., MacDonald, J.S., Alberts, A.W., Molon-Noblot, S., Chen, J.S., Lo, C.-Y.L., Greenspan, M.D., Allen, H., Durand-Cavagna, G., Jensen, R., Bailly, Y., Delort, P., and Duprat, P. (1988). Brain and optic system pathology in hypocholesterolemic dogs treated with a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.AmerJPathol 132(3), 427—43.
  • Beil, F.U., Schrameyer-Wernecke, A., Beisiegel, U., Greten, H., Karkas, J.D., Liou, R., Alberts, A.W., Eckardt, H.G., and Till, A.E. (1990). Lovastatin versus bezafibrate: efficacy, tolerability, and effect on urinary mevalonate. Cardiology 77(suppl. 4), 22—32.
  • Brown, M.S., and Goldstein, J.L. (1986). A receptor-mediated pathway for cholesterol homeostasis. Science 232, 34—47.[Free Full Text]
  • Cenedella, R.J. (1996). Cholesterol and cataracts. Surv Ophthalmol 40(4), 320— 36.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cheng, Q.W., Robison, Jr., G., and Zigler, Jr., J.S. (2002). Geranylgeranyl pyrophosphate counteracts and cataractogenic effect of lovastatin on cultured rat lenses. Exp Eye Res 75, 603—9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Choa, Y., Chen, J.S., Hunt, V.M., Kuron, G.W., Karkas, J.D., Liou, R., and Alberts, A.W. (1991). Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin. Euro J Clin Pharmacol 40(suppl. 1), S11— S14.[CrossRef]
  • Chylack, Jr., L.T., Mantell, G., Wolfe, J.K., Friend, J., and Rosner, B., The MSDRL Study Group. (1993). Lovastatin and the human lens; results of a two year study. Optometry Vision Sci 70(11), 937—43.
  • Corsini, A., Fumagalli, R., Paoletti, R., andBernini, F. (1996). Preclinical studies of fluvastatin. Drugs Today 32(suppl. A), 13—35.
  • Dalen, J.E., and Dalton, W.S. (1996). Does lowering cholesterol cause cancer? J Am Med Assoc 275(1), 67—9.[Abstract/Free Full Text]
  • de Vries, A.C.J., Vermee, M.A., Bloemendal, H., and Cohen, L.H. (1993a). Pravastatin and simvastatin differently inhibit cholesterol biosynthesis in human lens. Invest Ophthalmol Vis Sci 34, 377—84.[Abstract/Free Full Text]
  • de Vries, A.C.J., and Cohen, L.H. (1993b). Different effects of hypolipidemic drugs pravastatin and lovastatin on the cholesterol biosynthesis of the human ocular lens in organ culture and on the cholesterol content of the rat lens in vivo. Biochim Biophys Acta 1167, 63—9.[Medline] [Order article via Infotrieve]
  • Endo, A., Kuroda, M., and Yoshio Tsujita, M. (1976). ML-236A, ML-236B and ML-236C: new inhibitions of cholesterologenesis produced by Penicillium citrinum. J Antiobiotic 29, 1346—8.
  • Endo, A., Yoshio Tsujita, M., Kuroda, M., and Tanzawa, K. (1979). Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals. Biochim Biophys Acta 575, 266—76.[Medline] [Order article via Infotrieve]
  • Evans, M., and Rees, A. (2002). Effects of HMG-CoA reductase inhibitors on skeletal muscle: Are all statins the same? Drug Safety 25(9), 649— 63.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Farmer, J.A. (2001). Learning from the cerivastatin experience. Lancet 358, 1383—5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Farnsworth, W.H., Hoeg, J.M., Maher, M., Brittain, E.H., Sherins, R.J., and Brewer, Jr., H.B. (1987). Testicular function in Type II hyperlipoproteinemic patients treated with lovastatin (mevinolim) or neomycin. J Clin Endocrinol Metab 65, 546—50.[Abstract/Free Full Text]
  • Flint, O.P., Masters, B.A., Gregg, R.E., and Durham, S.K. (1997). HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture. Toxicol Appl Pharmacol 145, 99—110.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gaist, D., Jeppesen, U., Andersen, M., Garcia Rodriguez, L.A., Hallas, J., and Sindrug, S.H. (2002). Statins and risk of polyneuropathy. Neurology 58, 1333—7.[Abstract/Free Full Text]
  • Gerson, R.J., MacDonald, J.S., Alberts, A.W., Kornbrust, D.J., Majka, J.A., Stubbs, R.J., and Bokelman, D.L. (1989). Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors. Am J Med 87(suppl. 4A), 28S—38S.[Medline] [Order article via Infotrieve]
  • Gerson, R.J., MacDonald, J.S., Alberts, A.W., Chen, J., Yudkovitz, J.B., Greenspan, M.D., Rubin, L.F., and Bokelman, D.L. (1990). On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors. Exp Eye Res 50, 65—78.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gerson, R.J., Allen, H.L., Lankas, G.R., MacDonald, J.S., Alberts, A.W., and Bokelman, D.L. (1991). The toxicity of a fluorinated-biphenyl HMG-CoA reductase inhibitor in beagle dogs. Fundam Appl Toxicol 16, 320—9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Goldstein, J.L., and Brown, M.S. (1990). Regulation of the mevalonate pathway. Nature 343, 425—30.[CrossRef][Medline] [Order article via Infotrieve]
  • Hartman, H.A., Myers, L.A., Evans, M., Robison, R.L., Engstrom, R.G., and Tse, F.L.S. (1996). The safety evaluation of fluvastatin, an HMG-CoA reductase inhibitor, in beagle dogs and Rhesus monkeys. Fundam Appl Toxicol 29, 48—62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hodel, C. (2002). Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett 128, 159—68.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hoffman, W.F., Alberts, A.W., Anderson, P.S., Chen, J.S., Smith, R.L., and Willard, A.K. (1986). 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: 4-side chain ester derivatives of mevinolin. J Med Chem 29, 849—52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hrab, R.V., Hartman, H.A., and Cox, Jr., R.H. (1994). Prevention of fluvastatininduced toxicity, mortality, and cardiac myopathy in pregnant rats by mevalonic acid supplementation. Teratology 50, 19—26.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kannel, W.B., McGee, K., and Gordon, T. (1976). A general cardiovascular risk profile: the Framingham study. Am J Cardiol 38, 46—51.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Keys, A., Taylor, H.L., Blackburn, H., Brozek, J., Anderson, J.T., and Simonson, E. (1971). Mortality and coronary heart disease among men studied for 23 years. Arch Intern Med 128, 201—14.[Abstract/Free Full Text]
  • Kirby, T.J. (1967). Cataracts produced by triparanol (MER-29). Trans Amer Ophthal Soc 65, 493—543.
  • Kloss, M.W., Patrick, D.H., and MacDonald, J.S. (1991). Studies on the effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on the rodent forestomach. Fd Chem Toxicol 29(9), 621—8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Koga, T., Shimada, Y., Kuroda, M., Tsujita, Y., Hasegawa, K., and Yamazaki, M. (1990). Tissue selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim Biophys Acta 1045, 115—20.[Medline] [Order article via Infotrieve]
  • Komai, T., Shigeharra, E., Tokui, T., Koga, T., Ishigami, M., Kuroiwa, C., and Horiuchi, S. (1992). Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture. Biochem Pharmacol 43, 667—70.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kornbrust, D.J., MacDonald, J.S., Peter, C.P., Duchai, D.M., Stubbs, R.J., Germershausen, J.I., and Alberts, A.W. (1989). Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits. J Pharmacol Exp Ther 248(2), 498—505.[Abstract/Free Full Text]
  • Lankas, G.R., Cukierski, M.A., and Wise, L.D. (2004). The role of maternal toxicity in lovastatin-induced developmental toxicity. Develop Reprod Toxicol, in press.
  • Li, A.C., Tanaka, R.D., Callaway, K., Fogelman, A.M., and Edwards, P.A. (1988). Localization of 3-hydroxy-3-methylglutaryl CoA reductase and 3-hydroxy-3-methylglutaryl CoA Synthase in the rat liver and intestine is affected by cholestyramine and mevinolin. J Lipid Res 29, 781—96.[Abstract]
  • Lipid Research Clinics Program. (1984). The Lipid Research Clinics coronary primary prevention trail results. J Am Med Assoc 251(3), 365—74.[Abstract/Free Full Text]
  • MacDonald, J.S. (1995). Perspective on cataractogenic potential of HMG-CoA reductase inhibitors. Exp Eye Res 60, 97—101.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • MacDonald, J.S., Gerson, R.J., Kornbrust, D.J., Kloss, M.W., Prahalada, S., Berry, P.H., Alberts, A.W., and Bokelman, D.L. (1988). Preclinical evaluation of lovastatin. Amer J Cardiol 62, 16J—27J.[CrossRef][Medline] [Order article via Infotrieve]
  • Manson, M.J., Freyssinges, C., Ducrocq, M.B., and Stephenson, W.P. (1996). Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. Repro Tox 10, 439—46.[CrossRef]
  • Masters, B.A., Palmoski, M.J., Flint, O.P., Gregg, R.E., Wang-Iverson, D., and Durham, S.K. (1995). In vitro myotoxicity of the 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol 131, 163—74.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Minsker, D.H., MacDonald, J.S., Robertson, R.T., and Bokelman, D.L. (1983). Mevalonate supplementation of pregnant rats suppresses the teratogenicity of mevinolinic acid, A inhibitor of 3-hydroxy-3- methylglutaryl-coenzyme A reductase. Teratology 28, 449—56.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mosley, S.T., Kalinowski, S.S., Schafer, B., and Tanaka, R.D. (1989). Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens. J Lipid Res 30, 1411—20.[Abstract]
  • Muldoon, M.F., Barger, S.D., Ryan, C.M., Flory, J.D., Lehoczky, J.P., Matthews, K.A., and Manuck, S.B. (2002). Effects of lovastatin on cognitive function and psychological well-being. Amer J Med 108, 538— 46.[CrossRef]
  • Muscari, A., Puddu, G.M., and Puddu, P. (2002). Lipid-lowering drugs: are adverse effects predictable and reversible? Cardiology 97, 115—21.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nakahara, K., Kuriyama, M., Sonoda, Y., Yoshidome, H., Nakagawa, H., Fujiyama, J., Higuchi, I., and Osame, M. (1998). Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study. Toxicol Appl Pharmacol 152, 99—106.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • National Institutes of Health Consensus Development Conference. (1985). Lowering blood cholesterol to prevent heart disease. Nutr Rev 43(9), 283—5.[Web of Science][Medline] [Order article via Infotrieve]
  • Newman, T.B., and Hulley, S.B. (1996). Carcinogenicity of lipid-lowering drugs. J Amer Med Assoc 275(1), 55—60.[Abstract/Free Full Text]
  • Norman, D.J., Illingworth, D.R., Munson, J., and Hosenpud, J. (1988). Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. N Engl J Med 318, 46—47.[Web of Science][Medline] [Order article via Infotrieve]
  • Oms, P., Assie, N., Bruniquel, F., Degryse, A., van Haverbeke, G., and Delhon, A. (1995). Biochemical changes and morphological alterations of liver and kidney in hamsters after administration of the HMG-coenzyme A reductase inhibitor, simvastatin: prevention and reversibility by mevalonate. Pharmacol Toxicol 77, 391—6.[Web of Science][Medline] [Order article via Infotrieve]
  • Parker, T.S., McNamara, D.J., Brown, C.D., Kolb, R., Ahrens, Jr., E.H., Alberts, A.W., Tobert, J., Chen, J., and De Schepper, P.J. (1984). Plasma mevalonate as a measure of cholesterol synthesis in man. J Amer Soc Clin Invest 74, 795—804.[CrossRef]
  • Parker, T.S., McNamara, D.J., Brown, C., Garrigan, O., Kolb, R., Batwin, H., and Ahrens, Jr., E.H. (1982). Mevalonic acid in human plasma: relationship of concentration and circardian rhythm to cholesterol synthesis rates in man. Proc Natl Acad Sci USA 79, 3037—41.[Abstract/Free Full Text]
  • Pedersen, T.R., Berg, K., Cook, T.J., Faergeman, O., Haghfelt, T., Kjekshus, J., Miettinen, T., Musliner, T.A., Olsson, A.G., Pyorala, K., Thorgeirsson, G., Tobert, J.A., Wedel, H., and Wilhelmsen, L. (1996). Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian simvasatin survival study. Arch Intern Med 156, 2985—92.
  • Pierno, S., De Luca, A., Tricarico, D., Roselli, A., Natuzzi, F., Ferrannini, E., Laico, M., and Camerino, D.C. (1995). Potential risk on myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers. J Pharmacol Exp Thera 275(3), 1490—6.[Abstract/Free Full Text]
  • Prueksaritanont, T., Zhao, J.J., Ma, B., Roadcap, B.A., Tang, C., Qiu, Y., Liu, L., Lin, J.H., Pearson, P.G., and Baillie, T.A. (2002). Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Therap 301(3), 1042—51.[Abstract/Free Full Text]
  • Purvis, K., Tollefsrud, A., Rui, H., Haug, E., Norseth, J., Viksmoen, L., Ose, L., and Lund, H. (1992). Short-term effects of treatment with simvastatin on testicular function in patients with heterozygous familial hypercholesterolaemia. Eur J Clin Pharmacol 42, 61—4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rehm, S. (2000). Spontaneous testicular lesions in purpose-bred beagle dogs. Toxicol Pathol 28, 782—7.[Abstract/Free Full Text]
  • Reijneveld, J.C., Koot, R.W., Bredman, J.J., Joles, J.A., and Bar, P.R. (1996). Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats. Pediatric Res 39(6), 1028—35.[Web of Science][Medline] [Order article via Infotrieve]
  • Robinson, R., Suter, W., and Cox, R.H. (1994). Carcinogenicity and mutagenicity studies with fluvastatin, a new, entirely synthetic HMG-CoA reductase inhibitor. Fund Appl Toxicol 23, 9—20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Schaefer, W.H., Lawrence, J.W., Loughlin, A.F., Stoffregen, D.A., Mixson, L.A., Dean, D.C., Raab, C.E., Yu, N.X., Lankas, G.R., and Frederick, C.B. (2004). Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol Appl Pharmacol 194, 10—23.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Schmidt, J., Schmitt, C., and Hockwin, O. (1990). No lens changes caused by simvastatin results from a prospective drug safety study. Lens Eye Tox Res 7(3—4), 643—50.
  • Schmidt, J., Schmitt, C., Hockwin, O., Paulus, U., and Bergmann, K.V. (1994). Ocular drug safety and HMG-CoA reductase inhibitors. Ophthal Res 26, 352—60.
  • Shitara, Y., Itoh, T., Sato, H., Li, A.P., and Sugiyama, Y. (2003). Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304(2), 610—16.[Abstract/Free Full Text]
  • Singer, I.I., Kawka, D.W., Kazazis, D.M., Alberts, A.W., Chen, J.S., Huff, J.W., and Ness, G.C. (1984). Hydroxymethylglutarly-coenzyme A reductase-containing hepatocytes and distributed periportally in normal and mevinolin-treated rat livers. Proc Natl Acad Sci USA 81, 5556—60.[Abstract/Free Full Text]
  • Singer, I.I., Kawka, D.W., Scott, S., Bailey, P., Kloss, M.W., Majka, J., and MacDonald, J.S. (1991). Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme a reductase induce reductase accumulation and altered lamellar bodies in rat forestomach keratinocytes. Arteriosclerosis and Thrombosis 11, 1156—1165.[Abstract/Free Full Text]
  • Smith, C.C., Bernstein, L.I., Davis, R.B., Rind, D.M., and Shmerling, R.H. (2003). Screening for statin-related toxicity. Arch Intern Med 163, 688—92.[Abstract/Free Full Text]
  • Smith, P.F., Eydelloth, R.S., Grossman, S.J., Stubbs, R.J., Schwartz, M.S., Germershausen, J.I., Vyas, K.P., Kari, P.H., and MacDonald, J.S. (1991a). HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine a interaction and mechanism studies. J Pharmacol Exp Therap 257(3), 1225—35.[Abstract/Free Full Text]
  • Smith, P.F., Grossman, S.J., Gerson, R.J., Gordon, L.R., DeLuca, J.G., Majka, J.A., Wang, R.W., Germershausen, J.I., and MacDonald, J.S. (1991b). Studies on the mechanism of simvastatin-induced thyroid hypertrophy and follicular cell adenoma in the rat. Toxicol Pathol 19(3), 197—205.[Web of Science][Medline] [Order article via Infotrieve]
  • Smith, P.F., Eydelloth, R.S., Grossman, S.J., Stubbs, R.J., Schwartz, M.S., Germershausen, J.I., and MacDonald, J.S. (1992). Myopathy associated with hmg-coa reductase inhibitors (HMGRIs) and cyclosporin A: evaluation in a rat model. Euro Heart J 13(suppl. B), 2—6.[Abstract/Free Full Text]
  • Tobert, J.A. (2003). Lovastatin and beyond: the history of the HMG-CoAreductase inhibitors. Nat Rev 2, 517—26.
  • Tolman, K.G. (2000). Defining patient risks from expanded preventive therapies. Am J Cardiol 85(12A), 15E—19E.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Tolman, K.G. (2002). The liver and lovastatin. Am J Cardiol 89, 1374— 80.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Tomlinson, B., Chan, P., and Lan, W. (2001). How well tolerated are lipid-lowering drugs. Drugs Aging 18(9), 665—83.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ucar, M., Mjorndal, W., and Dahlqvist, R. (2000). HMG-CoA reductase inhibitors and myotoxicity. Drug Safety 22(6), 441—57.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • von Keutz, E., and Schluter, G. (1998). Preclinical safety evaluation of Cerivastatin, a novel HMG-CoA reductase inhibitor. Amer J Cardiol 82, 11J—17J.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Walsh, K.M., Albassam, M.A., and Clarke, D.E. (1996). Subchronic toxicity of atorvastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor, in beagle dogs. Toxicol Pathol 24(4), 468—76.[Abstract/Free Full Text]
  • Walsh, K.M., and Rothwell, C.E. (1999). Hepatic effects in beagle dogs administered atorvastatin, a 3-hydroxy-3-methylglutarly coenzyme A reductase inhibitor, for 2 Years. Toxicol Pathol 27(4), 395—401.[Abstract/Free Full Text]
  • Williams, D., and Feeley, J. (2002). Pharmacokinetic pharmacodynamic drug interaction with HMG-CoA reductase inhibitors. Clin Pharmacokin 41, 343—70.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wise, L.D., Cukierski, M.A., Lankas, G.R., and Skiles, G.L. (2000). The predominant role of maternal toxicity in lovastatin-induced developmental toxicity. Teratology 61, 444.
  • Ziegler, K., and Stunkel, W. (1992). Tissue-selective action of pravastatin due to hepatocellular uptake via sodium-independent bile acid transporter. Biochim Biophys Acta 1139, 203—9.[Medline] [Order article via Infotrieve]

Toxicologic Pathology, Vol. 32, No. 2 suppl, 26-41 (2004)
DOI: 10.1080/01926230490462057
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by MacDonald, J. S.
Right arrow Articles by Halleck, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MacDonald, J. S.
Right arrow Articles by Halleck, M. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?